go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Bayer Limited

Bayer Limited
The Atrium, Blackthorn Road, Dublin 18,
Telephone: +353 1 2999 313
Fax: +353 1 2061 456
Summary of Product Characteristics last updated on medicines.ie: 07/10/2011
SPC Adalat Retard 10 mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 07/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   26-Aug-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

Following approval of Company Core Data Sheet (CCDS) version #22, the following sections of the SPC have been updated.

Section 2.0, 4.2,4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 6.1 and section10.0
Updated on 16/09/2009 and displayed until 07/10/2011
Reasons for adding or updating:
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   02-Mar-2009
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

In section 10 ( Date of revision of the text) December 2008 is deleted and replaced with March 2009.
Updated on 26/01/2009 and displayed until 16/09/2009
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   12/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Changes following transfer of MAH from Bayer plc to Bayer Ltd.

Updated on 04/12/2008 and displayed until 26/01/2009
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
Date of revision of text on the SPC:   11/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Changes to Section 4.3, 4.4 and 4.6.
Updated on 17/11/2008 and displayed until 04/12/2008
Reasons for adding or updating:
  • New individual SPC (was previously included in combined SPC)
Date of revision of text on the SPC:   08/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

 
 
New individual SPC (was previously a combined SPC)
Updated on 24/09/2008 and displayed until 17/11/2008
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability
Date of revision of text on the SPC:   08/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

1. Name of the Medicinal Product
from:

Adalat retard 10 mg tablets.

 

Adalat retard 20 mg tablets.
 
to:

Adalat Retard 10 mg Prolonged-Release tablets

 

Adalat Retard 20 mg Prolonged-Release tablets.
 
2. Qualitative and Quantitative Composition
from:

Adalat retard 10 mg tablets: One film-coated, prolonged-release tablet contains 10 mg nifedipine.

 

Adalat retard 20 mg tablets: One film-coated, prolonged-release tablet contains 20 mg nifedipine.

 

For excipients, see 6.1.
 
to:
 

Adalat retard 10 mg tablets: One film-coated, prolonged-release tablet contains 10 mg nifedipine.

 

Adalat retard 20 mg tablets: One film-coated, prolonged-release tablet contains 20 mg nifedipine.

 

Excipients: Lactose monohydrate 10.00 mg per tablet.

 

For a full list of excipients, see section 6.1.
 
4.8    Undesirable effects
from:

ADRs listed under ¡°common¡± were observed with a frequency below 3% with the exception of oedema (9.9%) and headache (3.9%). ADRs derived from post marketing reports (status:15 Feb 2006) are printed in bold italic.

 

Clinical

Description

Common >1% to <10%

Uncommon  

>0.1% to <1%

Rare >0.01% to <0.1%

Very Rare

<0.01%

 
to:

Adverse drug reactions (ADRs) based on placebo-controlled studies with nifedipine sorted by CIOMS III categories of frequency (clinical trial data base: nifedipine n=2,661; placebo n=1,486; status: 22 Feb 2006 and the ACTION study: nifedipine n=3,825; placebo n=3,840) are listed below: ADRs listed under ¡°common¡± were observed with a frequency below 3% with the exception of oedema (9.9%) and headache (3.9%). ADRs derived from post marketing reports (status: 31 Mar 2006) are printed in bold italic.

 

Clinical

Description

Common ¡Ý1% to <10%

Uncommon  

¡Ý0.1% to <1%

Rare ¡Ý0.01% to <0.1%

Very Rare

<0.01%

 
from:
Anaphylactic/ anaphylactoid reaction
 
to:
Anaphylactic/ anaphylactoid reaction
 
from:
Dyspnoea
 
to:
Dyspnoea
 
from:
Vomiting
 
to:
Vomiting
 
10. Date of Revision of the Text
from:
April 2007
 
to:

August 2008

Updated on 28/05/2008 and displayed until 24/09/2008
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   04/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Changes have been made to Section 4.2, Section 4.5, Section 4.8, Section 4.9, Section 5.1, Section 5.2 and Section 5.3.

 

Section 10. Date of Revision of the Text has been changed to

“April 2007”

 

Updated on 30/08/2006 and displayed until 28/05/2008
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   02/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 4.9, paragraph on Clinical Effects/Symptoms has been re-written and the following deleted:

1.                   Cardiac effects may include heart block, AV dissociation and asystole

2.                   Other toxic effects include nausea, vomiting, drowsiness, dizziness, confusion, lethargy, flushing

 

The treatment section, ‘use Ipecacuanha should be given to children’ and ‘Activated charcoal should be given in 4-hourly doses of 25g for adults, 10g for children. Blood pressure, ECG, central arterial pressure, pulmonary wedge pressure, urea and electrolytes should be monitored’ has also been deleted.

 

Updated on 01/02/2005 and displayed until 30/08/2006
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Updated on 13/06/2003 and displayed until 01/02/2005
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Nifedipine

Versions

 
07/10/2011 to Current
16/09/2009 to 07/10/2011
26/01/2009 to 16/09/2009
04/12/2008 to 26/01/2009
17/11/2008 to 04/12/2008
24/09/2008 to 17/11/2008
28/05/2008 to 24/09/2008
30/08/2006 to 28/05/2008
01/02/2005 to 30/08/2006
13/06/2003 to 01/02/2005
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo